22722 29TH DR. SE, SEATTLE, WA
Reports First Quarter 2026 Financial Results and Provides Business Updates
Announces Up to $354 Million Private Placement
Financial Results, Press Release
Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Changes in Board, Management or Compensation
Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
Announces Pricing of $45.0 Million Underwritten Public Offering
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
Submission Upload
Correspondence
Post-Effective Amendment to Registration Statement